Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study

January 29, 2015. This case control study evaluated whether the use of incretin-based drug therapy (glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors) in type 2 diabetes was associated with an elevated risk of acute pancreatitis. Data were obtained from a nationwide population-based Danish medical database (12,868 patients with a first-time hospitalization for acute pancreatitis between 2005 and 2012, and 128,680 matched controls). Investigators adjusted for a history of gallstones, alcoholism, obesity, and other comorbidities, as well as the use of medications associated with pancreatitis. Eighty-nine pancreatitis patients (0.69%) and 684 control patients (0.53%) were ever users of incretins (adjusted odds ratio 0.97 [95% confidence interval, 0.76-1.23]). The investigators concluded that the use of incretin-based drugs did not appear to be associated with an elevated pancreatitis risk. You can read the full study abstract here."